Skip to content
Medical Health Aged Care

Survey reveals what’s standing in the way of good health

For immediate release - December, 4 2023 2 mins read

Aussies are being urged to prioritise their health and wellbeing with research revealing more than 40 per cent feel cost or time pressures are the main barrier standing in their way.

 

With the end of year approaching, Australians are being encouraged to make the most from their health insurance and book any medical appointments they might have forgotten or missed in 2023.

 

The Bupa Pulse Check study also revealed that of the 38 per cent of Australians who say they’re struggling to maintain their health and wellbeing, 50 per cent feel cost was a barrier with the survey also showing women faced more hurdles than men when it comes to improving their health and wellbeing.

 

Bupa health insurance data shows dental check-ups were the most common extras claimed with optical, physiotherapy, mental health and pharmacy also among the most common claims.

 

Bupa Dental Managing Director Dr Ros Blakley said addressing cost of living issues for patients was a major focus in the current inflationary environment and now offers gap-free simple dental fillings, mouthguards and check-ups to health insurance members who visit Bupa Dental.

 

“With the average filling costing about $220 we know this will be a welcome change for our customers,” Dr Blakley said.

 

“If you have been too busy and haven’t had a dental check-up this year, it’s definitely a good idea to book one in now while appointments are still available for 2023 as regular dental checks are vital in ensuring the health of your mouth along with your general health,”.

 

The lead-up to Christmas is the busiest time of the year to secure common appointments like dental check-ups, eye-tests and physio appointments as people look to get their yearly check-ups and use up their Extras limits before their health insurance Extras reset on January 1, 2024.

 

Bupa Optical appointments peak during December and experience a 30 per cent increase in appointments compared to the yearly average with customers looking to purchase new prescription sunglasses with the holidays approaching or new glasses while they still have their 2023 Extras benefits available.

 

Bupa Health Insurance Director Andrew Wilkinson said: “Now is the time to tick off the things on your to-do list before the busy festive season begins.

 

“It’s also a good time to review your policy to make sure it meets your current health and wellbeing needs.”

 

Australians needing their teeth or eyes checked should contact their local Bupa Dental practice or Bupa Optical store respectively to ensure they can secure an appointment before the end of the year.

 

To find your nearest Bupa Dental practice visit here

 

To find your nearest Bupa Optical store visit here

 

Please contact:

Eli Grynberg

External Communications Manager, Bupa

Email: eli.grynberg@bupa.com.au
Mob: 0401 135 713

 

 

 

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.